Acute Lymphoblastic Leukemia Clinical Trials at the Mario Lemieux Center for Blood Cancers

This Phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back after a period of improvement or has not responded to treatment. Monoclonal antibodies, such as blinatumomab, nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

Principal Investigator: Kathleen Dorritie, MD
Sponsor: National Cancer Institute

View eligibility criteria and the full trial at ClinicalTrials.gov.